Ezetimibe/Rosuvastatin
AssetSmall molecule
Dual inhibition of intestinal cholesterol absorption via NPC1L1 and hepatic cholesterol synthesis via HMGCR.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- Indications
- 2
- Trials
- 488
- Developers
- 1
Indications
2Hypercholesterolemia
Phase 3COMPLETEDNCT07564726clinicaltrials.gov7 Oct 2026
Hypertension
Phase 3COMPLETEDNCT07564726clinicaltrials.gov7 Oct 2026
- Targets and what it contains4
- Owner and partners1
- Trials488
- Evidence for its targets3
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 2 sources